Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

124 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Post-Transplantation Cyclophosphamide-Based Graft- versus-Host Disease Prophylaxis with Nonmyeloablative Conditioning for Blood or Marrow Transplantation for Myelofibrosis.
Jain T, Tsai HL, DeZern AE, Gondek LP, Elmariah H, Bolaños-Meade J, Luznik L, Fuchs E, Ambinder R, Gladstone DE, Imus P, Webster J, Prince G, Ghiaur G, Smith BD, Ali SA, Ambinder A, Dalton WB, Gocke CB, Huff CA, Gojo I, Swinnen L, Wagner-Johnston N, Borrello I, Varadhan R, Levis M, Jones RJ. Jain T, et al. Among authors: borrello i. Transplant Cell Ther. 2022 May;28(5):259.e1-259.e11. doi: 10.1016/j.jtct.2022.02.004. Epub 2022 Feb 11. Transplant Cell Ther. 2022. PMID: 35158092 Free PMC article.
New Developments in the Therapy of Acute Myelocytic Leukemia.
Gorin NC, Estey E, Jones RJ, Levitsky HI, Borrello I, Slavin S. Gorin NC, et al. Among authors: borrello i. Hematology Am Soc Hematol Educ Program. 2000:69-89. doi: 10.1182/asheducation-2000.1.69. Hematology Am Soc Hematol Educ Program. 2000. PMID: 11701536
This review examines the search for new agents and new modes of therapy. In Section I, Dr. Estey discusses new agents directed at various targets, such as CD33, angiogenesis, inappropriately methylated (suppressor) genes, cell cycle checkpoints, proteosomes, multidrug resi …
This review examines the search for new agents and new modes of therapy. In Section I, Dr. Estey discusses new agents directed at var …
Long-term follow-up of T cell-depleted allogeneic bone marrow transplantation in refractory multiple myeloma: importance of allogeneic T cells.
Huff CA, Fuchs EJ, Noga SJ, O'Donnell PV, Ambinder RF, Diehl L, Borrello I, Vogelsang GB, Miller CB, Flinn IA, Brodsky RA, Marcellus D, Jones RJ. Huff CA, et al. Among authors: borrello i. Biol Blood Marrow Transplant. 2003 May;9(5):312-9. doi: 10.1016/s1083-8791(03)00075-2. Biol Blood Marrow Transplant. 2003. PMID: 12766881 Free article.
Graft-versus-host reactions and the effectiveness of donor lymphocyte infusions.
Huff CA, Fuchs EJ, Smith BD, Blackford A, Garrett-Mayer E, Brodsky RA, Flinn IW, Ambinder RF, Borrello IM, Matsui WH, Vogelsang GB, Griffin CA, Luznik L, Jones RJ. Huff CA, et al. Biol Blood Marrow Transplant. 2006 Apr;12(4):414-21. doi: 10.1016/j.bbmt.2005.11.520. Biol Blood Marrow Transplant. 2006. PMID: 16545725 Free article. Clinical Trial.
Induction of autologous graft-versus-host disease: results of a randomized prospective clinical trial in patients with poor risk lymphoma.
Bolaños-Meade J, Garrett-Mayer E, Luznik L, Anders V, Webb J, Fuchs EJ, Huff CA, Matsui W, Borrello IM, Brodsky R, Kasamon YL, Swinnen LJ, Flinn IW, Ambinder RF, Jones RJ, Hess AD, Vogelsang GB. Bolaños-Meade J, et al. Biol Blood Marrow Transplant. 2007 Oct;13(10):1185-91. doi: 10.1016/j.bbmt.2007.06.011. Epub 2007 Aug 3. Biol Blood Marrow Transplant. 2007. PMID: 17889355 Free PMC article. Clinical Trial.
Clonogenic multiple myeloma progenitors, stem cell properties, and drug resistance.
Matsui W, Wang Q, Barber JP, Brennan S, Smith BD, Borrello I, McNiece I, Lin L, Ambinder RF, Peacock C, Watkins DN, Huff CA, Jones RJ. Matsui W, et al. Among authors: borrello i. Cancer Res. 2008 Jan 1;68(1):190-7. doi: 10.1158/0008-5472.CAN-07-3096. Cancer Res. 2008. PMID: 18172311 Free PMC article.
Myeloablative allogeneic bone marrow transplant using T cell depleted allografts followed by post-transplant GM-CSF in high-risk myelodysplastic syndromes.
Warlick ED, O'Donnell PV, Borowitz M, Grupka N, Decloe L, Garrett-Mayer E, Borrello I, Brodsky R, Fuchs E, Huff CA, Luznik L, Matsui W, Ambinder R, Jones RJ, Smith BD. Warlick ED, et al. Among authors: borrello i. Leuk Res. 2008 Sep;32(9):1439-47. doi: 10.1016/j.leukres.2007.12.017. Epub 2008 Feb 7. Leuk Res. 2008. PMID: 18261793 Free PMC article.
HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide.
Luznik L, O'Donnell PV, Symons HJ, Chen AR, Leffell MS, Zahurak M, Gooley TA, Piantadosi S, Kaup M, Ambinder RF, Huff CA, Matsui W, Bolaños-Meade J, Borrello I, Powell JD, Harrington E, Warnock S, Flowers M, Brodsky RA, Sandmaier BM, Storb RF, Jones RJ, Fuchs EJ. Luznik L, et al. Among authors: borrello i. Biol Blood Marrow Transplant. 2008 Jun;14(6):641-50. doi: 10.1016/j.bbmt.2008.03.005. Biol Blood Marrow Transplant. 2008. PMID: 18489989 Free PMC article. Clinical Trial.
124 results